Evidence supporting the use of: Immunoglobulin
For the health condition: Myasthenia Gravis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Immunoglobulin, specifically intravenous immunoglobulin (IVIG), is scientifically validated for use in treating Myasthenia Gravis (MG). IVIG is composed of pooled IgG antibodies from healthy donors and is used as an immunomodulatory therapy. The rationale behind its use in MG, an autoimmune disorder characterized by antibodies against acetylcholine receptors at the neuromuscular junction, is that IVIG can modulate the immune response. This is achieved through several mechanisms: neutralization of pathogenic autoantibodies, inhibition of complement activation, and modulation of Fc receptor-mediated activity on immune cells.

Multiple randomized controlled trials and systematic reviews have demonstrated the efficacy of IVIG in managing acute exacerbations of MG, including myasthenic crises. For example, a pivotal randomized trial (The Myasthenia Gravis Study Group, 1997) compared IVIG to plasma exchange and showed equivalent efficacy in improving muscle strength during acute worsening of symptoms. Subsequent meta-analyses and guideline statements from organizations such as the American Academy of Neurology (AAN) and the European Federation of Neurological Societies (EFNS) support the use of IVIG as a second-line or adjunctive therapy, especially when rapid improvement is needed or when other immunosuppressants are ineffective or contraindicated.

While IVIG is not typically used as a maintenance therapy for stable MG, its role in acute management is well established in clinical practice guidelines and supported by high-quality evidence.

More about immunoglobulin
More about Myasthenia Gravis

Other ingredients used for Myasthenia Gravis

vitamin D

Products containing immunoglobulin

We currently have no products on Vitabase that contain this ingredient.